Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an asthma drug tame this brutal blistering disease?

NCT ID NCT04206553

Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether dupilumab, a drug already used for asthma and eczema, can help people with bullous pemphigoid, a painful blistering skin condition. 106 adults received either dupilumab or a placebo, plus standard steroid treatment. The main goal was to see if more people could achieve long-term remission without needing steroids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dupilumab (Dupixent)
What this could lead to
If successful, dupilumab could offer a new treatment option for bullous pemphigoid, potentially reducing the need for long-term steroids.
What could go wrong
This is a mid-stage trial with only 106 participants. Results may not apply to all patients, and side effects or lack of effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

106 people

The number who actually took part.

Started

Oct 2020

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Patients must have characteristic clinical features of bullous pemphigoid (BP) (eg, urticarial or eczematous or erythematous plaques, bullae, pruritus) at the screening and baseline visits. * Study participants are required to have a confirmed diagnosis of BP based on histopathology, immunopathology, and serology at the baseline visit, as defined in the protocol. * Bullous Pemphigoid Disease Area Index (BPDAI) activity score ≥24 at baseline and screening visits. * Baseline peak pruritus NRS score for maximum itch intensity ≥4 * Karnofsky performance status score ≥50% at the screening visit. Key Exclusion Criteria: * Forms of pemphigoid other than classic BP (eg, Brunsting-Perry cicatricial pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita, or BP with concomitant pemphigus vulgaris) * Patients who are receiving treatments known to cause or exacerbate BP (eg, angiotensin converting enzyme inhibitors, penicillamine, furosemide, phenacetin, dipeptidyl peptidase 4 inhibitor) who have not been on a stable dose of these medications for at least 4 weeks prior to the screening visit * Have ever received treatment with an IL-4 or IL-13 antagonist such as dupilumab, tralokinumab, or lebrikizumab. * Treatment with systemic corticosteroids within 7 days before the baseline visit * Treatment with topical corticosteroids of medium potency or higher, topical calcineurin inhibitor, or topical crisaborole within 7 days before the baseline visit * Treatment with non-steroidal immunosuppressive/immunomodulating drug(s) (eg, mycophenolate mofetil, azathioprine, or methotrexate) within 4 weeks before the baseline visit. * Treatment with BP-directed biologics as follows: * Any cell-depleting agents including but not limited to rituximab: within 12 months before the baseline visit, or until lymphocyte and CD 19+ lymphocyte count returns to normal, whichever is longer * Other biologics (such as IL-5 inhibitors benralizumab or mepolizumab): within 5 half-lives (if known) or 16 weeks prior to the baseline visit, whichever is longer * Intravenous immunoglobulin within 16 weeks prior to the baseline visit NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bullous pemphigoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bullous pemphigoid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bullous pemphigoid

Contacts and locations

Locations

  • Regeneron Study Site

    Scottsdale, Arizona, 85259, United States

  • Regeneron Study Site

    Redwood City, California, 94063, United States

  • Regeneron Study Site

    Farmington, Connecticut, 06030, United States

  • Regeneron Study Site

    Miami, Florida, 33125, United States

  • Regeneron Study Site

    Iowa City, Iowa, 52242, United States

  • Regeneron Study Site

    Boston, Massachusetts, 02116, United States

  • Regeneron Study Site

    Chapel Hill, North Carolina, 27516, United States

  • Regeneron Study Site

    Portland, Oregon, 97239, United States

  • Regeneron Study Site

    Philadelphia, Pennsylvania, 19104, United States

  • Regeneron Study Site

    Murray, Utah, 84107, United States

  • Regeneron Study Site

    Kogarah, New South Wales, 2217, Australia

  • Regeneron Study Site

    Box Hill, Victoria, 3128, Australia

  • Regeneron Study Site

    Bobigny, 93009, France

  • Regeneron Study Site

    Bordeaux, 33000, France

  • Regeneron Study Site

    Lille, 59037, France

  • Regeneron Study Site

    Nice, 06200, France

  • Regeneron Study Site

    Paris, 75010, France

  • Regeneron Study Site

    Rouen, 76031, France

  • Regeneron Study Site

    Münster, North Rhine-Westphal, 48149, Germany

  • Regeneron Study Site

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Regeneron Study Site

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Regeneron Study Site

    Berlin, 10117, Germany

  • Regeneron Study Site

    Buxtehude, 21614, Germany

  • Regeneron Study Site

    Erlangen, 91054, Germany

  • Regeneron Study Site

    Freiburg im Breisgau, 79104, Germany

  • Regeneron Study Site

    Munich, 80802, Germany

  • Regeneron Study Site

    Stuttgart, 70178, Germany

  • Regeneron Study Site

    Hirosaki, 036-8563, Japan

  • Regeneron Study Site

    Ichinomiya, 491-8558, Japan

  • Regeneron Study Site

    Osaka, 545-8586, Japan

  • Regeneron Study Site

    Sapporo, 060-8648, Japan

  • Regeneron Study Site

    Tokyo, 160-8582, Japan

  • Regeneron Study Site

    Krakow, Lesser Poland Voivodeship, 31-147, Poland

  • Regeneron Study Site

    Badalona, Barcelona, 08916, Spain

  • Regeneron Study Site

    Madrid, 28034, Spain

  • Regeneron Study Site 2

    Dresden, Saxony, 01307, Germany

  • Regeneron Study site

    Marburg, 35043, Germany

  • Regeneron Study site

    Kurume, Hukuoka, 830-0011, Japan

  • Regeneron Study site'

    Magdeburg, 39120, Germany

  • Regeneron Study site'

    Ossy, 42-624, Poland

  • Regeneron Study site'

    Wroclaw, 50566, Poland

  • Regeneron study Site

    Birmingham, Alabama, 35233, United States

  • Regeneron study Site

    Orlando, Florida, 32827, United States

  • Regeneron study Site

    Ann Arbor, Michigan, 48109-5314, United States

  • Regeneron study Site

    Providence, Rhode Island, 02908, United States

  • Regeneron study Site

    Charlottesville, Virginia, 22903, United States

  • Regeneron study Site

    Afula, 1834111, Israel

  • Regeneron study Site

    Petah Tikva, 49100, Israel

  • Regeneron study Site

    Tel Aviv, 6423906, Israel

  • Regeneron study Site

    Madrid, 28046, Spain

  • Regeneron study Site

    Pamplona, 31008, Spain

  • Regeneron study Site

    Taipei, Zhongzheng District, 10002, Taiwan

  • Regeneron study Site

    Taoyuan City, 33305, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.